severe neurologic disease
Conditions
Interventions
Remimazolam group:Rimazolam (load dose 0.2mg/kg, maintenance dose 0.1mg/kg/h~0.45mg/kg/h)
Dexmedetomidine group:Dexmedetomidine (loading dose 1ug/kg, maintenance dose 0.2-0.7ug /kg/h)
Sponsors
Neurosurgery of Zhangjiajie City People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Basal ganglia cerebral hemorrhage: 1.Age 18~65 years; 2.History of hypertension; 3.Spontaneous cerebral hemorrhage (except re-bleeding); 4.Location: Basal ganglia (caudate nucleus, lenticular nucleus, internal capsule, external capsule, nucleus pleura, external capsule); 5.Cerebral hemorrhage breaks into or does not break into the ventricle. Image data is ordered by neurosurgeon + imaging doctor. Aneurysmal subarachnoid hemorrhage: 1.Age 18~65 years old; 2.Spontaneous subarachnoid hemorrhage; 3.Perfect head CTA or DSA to indicate a ruptured aneurysm; 4.With or without intracerebral hematoma; 5.Cerebral hemorrhage breaks into or does not break into the ventricle. Image data is ordered by neurosurgeon + imaging doctor. Brain Injury: 1.Age 18~65 years old; 2.History of trauma; 3.Head CT suggests intracranial hemorrhage, with or without intracerebral hematoma; 4.With or without ventricular hemorrhage; 5.Surgery is clearly indicated and requires surgical treatment. Image data is ordered by neurosurgeon + imaging doctor. Suspected vascular disease or tumor stroke needs to complete related examinations.
Exclusion criteria
Exclusion criteria: Basal ganglia cerebral hemorrhage: 1.Basic diseases of liver and kidney dysfunction (on admission); 2.Severe cardiopulmonary disease (on admission); 3.History of related drug allergy; 4.Severe brain herniation who refuses surgery; 5.History of mental disorders; 6.Unexpected events during treatment need to terminate the trial. Aneurysmal subarachnoid hemorrhage: 1.Severe cardiopulmonary disease (on admission); 2.Basic diseases of liver and kidney dysfunction (on admission); 3.History of related drug allergy; 4.Surgery indications clearly refused surgery, or rebleeding condition worsened; 5.History of mental disorders; 6.Unexpected events during treatment need to terminate the trial. Brain Injury: 1.Severe cardiopulmonary disease (on admission); 2.Basic medical history of liver and kidney dysfunction (at the time of admission); 3.History of related drug allergy; 4.Surgery indications clearly refused surgery, or rebleeding condition worsened; 5.History of mental disorders; 6.Suspicious stroke with arteriovenous malformation, aneurysm or tumor; 7.Unexpected events during treatment need to terminate the trial; 8.There are obvious neurological symptoms and signs in the history of previous brain diseases; 9.Multiple injuries throughout the body accompanied by other organ dysfunction.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time required to reach sedation depth;Single medication to achieve target sedation rate;Success rate of achieving target sedation; | — |
Secondary
| Measure | Time frame |
|---|---|
| ICP value at each time point between each group during maintenance dose; | — |
Countries
China
Contacts
Public ContactHu Guancheng
Neurosurgery of Zhangjiajie City People's Hospital
Outcome results
None listed